Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 3,210.00p 3,170.00p 3,250.00p 3,210.00p 3,210.00p 3,210.00p 23,394 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 8.0 6.9 110.2 29.1 165.02

Bioventix Share Discussion Threads

Showing 901 to 923 of 925 messages
Chat Pages: 37  36  35  34  33  32  31  30  29  28  27  26  Older
DateSubjectAuthorDiscuss
03/12/2018
11:39
You have to pay more for the kind of talent it takes to financially engineer what has happened at CAKE
steptoes yard
03/12/2018
10:54
Yes, but I'm willing to hang on to see how the Troponin rollout goes.
stepone68
03/12/2018
10:40
Fantastic business and I am a very happy long term holder but anyone else think the valuation is starting to look stretched?
s_a_b
03/12/2018
10:25
Buoyancy over last week the result of Mello presentation?
spann_703
03/12/2018
09:47
Unstoppable share!
igbertsponk
22/11/2018
11:12
Here is your chance to meet with Bioventix: Using this unique discount code, ADVFN25, you will be able to get £25 off at Mello London 2018, a 2 day investor conference from the 26th – 27th November 2018 at the Clayton Hotel, Chiswick, London. Http://melloevents.com/mello-london/ Tickets are normally priced at £99 for two days and £79 for one. Type in ADVFN25 as the discount code. Many Thanks and take advantage of this premium offer. See you there.
advfn_sales
18/11/2018
22:34
Here is the full two day programme schedule for MelloLondon including Bioventix Http://melloevents.com/wp-content/uploads/2018/11/MT16.11v2.pdf It is jam packed full of about 75 company presentations, lots of top quality speakers and panel sessions plus workshops to help with investment style and techniques etc. The pre event fun starts on the Sunday evening with a dinner and investor quiz hosted by John Lee but the main conference begins on Monday 26th November at 9am through to Tuesday 27th in the evening so do come and join us as there are still 97 tickets left... Http://melloevents.com/mello-london/ See you there.
davidosh
12/11/2018
11:40
Found a mention in this Telegraph interview with Keith Ashworth-Lord who holds a lot in his Buffettology fund:https://www.telegraph.co.uk/investing/funds/buffett-copycat-investor-buy-retro-company-immune-tech-revolution/amp/
s_a_b
12/11/2018
10:33
Maybe reinvestment of dividends
valustar1
12/11/2018
09:35
That's quite a jump this morning! Has the share been tipped somewhere?
s_a_b
11/11/2018
20:54
Just to mention that Peter Harrison of Bioventix will be presenting at our MelloLondon investor event in Chiswick W4 next month. MelloLondon is a two day event and starts on Monday 26th November through to Tuesday 27th November and BVXP will be on the first day.... You can find out more here... Http://melloevents.com/mello-london/ There will be 60 quality companies exhibiting and presenting plus some very well known investors, entrepreneurs, fund managers and market commentators providing excellent keynote talks on a range of investment subjects. A number of investment workshops will be available each day and a ShareSoc MasterClass on the final day. Peter will also feature in a session on successful CEO's and what investors should be looking for in a CEO that will help deliver outperformance.
davidosh
18/10/2018
12:20
Well, it would appear that Abbott have been developing a PoC test for troponin. The Abbott press release: Http://abbott.mediaroom.com/2018-10-17-New-Study-Shows-Abbotts-Novel-Diagnostic-Test-has-the-Potential-to-Demonstrate-Gold-Standard-Accuracy-and-Speed-Which-Could-Help-Rule-Out-Heart-Attacks-Earlier-at-the-Point-of-Care The published research: Https://jamanetwork.com/journals/jamacardiology/fullarticle/2705683#199769539 Research conclusion: "The I-Stat TnI-Nx assay represents an advance in point-of-care troponin technology. This preliminary study suggests its performance could enable it to be used to rapidly and safely to rule out myocardial infarction in a large proportion of patients with symptoms suggestive of acute coronary syndrome."
gsbmba99
18/10/2018
08:47
Thanks gsbmba99 for the reference to the future medicine review. Clearly, for rule-out of AMI, there is an urgent need for point-of-care testing of cardiac biomarkers, and to date, there is no POCT device that can achieve the levels of sensitivity required to provide accurate measurement of troponin or cMyC . Several things arise from this: 1) Peter Harrison is ahead of the curve (with his work on cMyC), further evidence that he's a great CEO. 2) POCT is the way forward. The high sensitivity Troponin assays on a large analyser can only be a stop gap solution. A stop gap, however, that may be here for 5-10 years. 4) To quote the article,"Emergency physicians are caught up in a sensitivity/specificity quagmire", more sensitive assays like cMyC are required Rationale: no A&E doc wants to be sending samples off to the lab in such an urgent situation, they need a machine/assay system right in the A&E dept close to where the blood sample is taken, giving a result in minutes. So what's the impact for BVXP? Well the troponin revenue stream may not be as permanent as presently envisaged, mind you 5-10 years is pretty good. There maybe a few POCT manufacturers beating a path to BVXP's door
rzbrdbe
17/10/2018
12:49
This is a good overview: Https://www.futuremedicine.com/doi/10.2217/bmm-2018-0176 I imagine the trick will be finding a PoC device that has the required level of sensitivity. I didn't see any PoC makers associated with the project. There appear to be a handful of UK organisations contributing to the effort (see disclosures in futuremedicine article). Patent held by KCL. If you ski, maybe you can take part in their fundraiser next year ( Https://alumni.kcl.ac.uk/news-features/carving-a-turn-for-cardiology-research )
gsbmba99
17/10/2018
12:40
According to research revealed in June ( Https://www.bhf.org.uk/what-we-do/news-from-the-bhf/news-archive/2018/june/heart-attack-blood-test-sensitive-enough-to-be-used-in-portable-device ): "In patients who did suffer heart attacks, the protein was present in high enough concentrations 95 per cent of the time for an on-the spot diagnosis. Importantly, the cMyC test outperformed the existing troponin test, which was only capable of diagnosing around 40 per cent of patients in this way."
gsbmba99
17/10/2018
12:34
Found a few articles relating to cardiac MyC which BVXP recently revealed is an experimental antibody they are working on. It caused a bit of a stir on the board about a year ago. As I understand it, a number of biomarkers "spike" and then decline in the immediate aftermath of a heart attack. MyC appears to be the first to "spike". The literature seems to suggest that it has similar rule in characteristics (presence of the biomarker indicates a heart attack) to troponin but better rule out (absence of the biomarker indicates no heart attack). Https://blog.bhf.org.uk/who-does-heart-attack-test-better-troponin-or-cmyc-150ddeafc135
gsbmba99
16/10/2018
09:59
Job done with BUR so moving on to BVXP?
valuehustle
16/10/2018
09:50
very expensive in present conditions £15 target
opodio
16/10/2018
09:46
Nice find, gsbmba, keep it up! Article didn't seem to identify a mechanism for other forms of organ failure. Harrison, bless him, did respond with a link to the talk. apad😎
apad
16/10/2018
09:39
"High relative troponin I concentrations in the blood of patients with chronic obstructive pulmonary disease (COPD) has been found to be a remarkably powerful predictor of all-cause mortality" ( Https://www.the-hospitalist.org/hospitalist/article/175407/copd/troponin-i-powerful-all-cause-mortality-risk-marker-copd ) and ( hxxp://www.chestnet.org/~/media/chesnetorg/Publications/Documents/CHEST%20Physician/Vol%2013%202018/102018.ashx ) Supportive for developing troponin market beyond just presentation at A&E for chest pain.
gsbmba99
15/10/2018
10:54
Indeed, gsbmba99, I now feel embarrassed at sending the email. As a friend emailed me: "Would be nice if all CEOs were like Harrison." apad
apad
15/10/2018
10:32
Apad - as luck would have it, Peter addresses your comment directly at 30:15 of the recently posted video.
gsbmba99
15/10/2018
07:33
Bioventix ShareSoc presentation: October 2018 By Peter Harrison, CEO Includes FY results for ye 30.6.18. Https://www.piworld.co.uk/2018/10/15/bioventix-bvxp-sharesoc-presentation-october-2018/ Overview - 00:29 Location and skills - 00:54 Automated blood testing - 01:26 Creating antibodies - 05:35 Why SMA’s? (Testosterone) - 07:49 Why SMA’s? (Troponin) - 10:04 Financial highlights 17/18 - 12:00 BVXP sales 17/18 product mix - 12:58 Key financials - 14:50 New Troponin assays - 15:46 Pipeline Development 2018 - 16:18 Business dynamics - 18:40 Selected shareholder base - 22:05 Bioventix Directors - 22:42 Conclusion and outlook – 23:19 Q&A - 24:39
tomps2
Chat Pages: 37  36  35  34  33  32  31  30  29  28  27  26  Older
Your Recent History
LSE
BVXP
Bioventix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181213 06:36:15